Originally published In Press as doi:10.1074/jbc.M206726200 on September 6, 2002
J. Biol. Chem., Vol. 277, Issue 45, 43079-43088, November 8, 2002
High Level of Uncoupling Protein 1 Expression in Muscle of
Transgenic Mice Selectively Affects Muscles at Rest and Decreases Their
IIb Fiber Content*
Elodie
Couplanab,
Chantal
Gellya,
Marc
Gouberncd,
Christophe
Fleurya,
Bruno
Quessone,
Mathieu
Silberbergf,
Eric
Thiaudièree,
Philippe
Mateog,
Michel
Lonchampth,
Nigel
Levensh,
Catherine
de Montrionh,
Silvia
Ortmanni,
Susanne
Klausi,
Maria-del-Mar
Gonzalez-Barrosoa,
Anne-Marie
Cassard-Doulciera,
Daniel
Ricquiera,
A. Xavier
Bigardf,
Philippe
Dioleze, and
Frédéric
Bouillaudaj
From the a Ceremod CNRS UPR9078, 9 rue Jules Hetzel, 92190 Meudon, France, the c Laboratoire de Nutrition et
Sécurité Alimentaire, INRA domaine de Vilvert, 78352 Jouy
en Josas Cedex, France, the e Resonance Magnétique des
Systèmes Biologiques, CNRS UMR5536, université Victor
Segalen Bordeaux 2, 146 rue Leo-Saignat, F-33076 Bordeaux, France, the
f Unité Bioénergétique et environnement,
Centre de Recherches du Service de Santé des Armées, 38702 La Tronche Cedex, France, the g INSERM U446 Université de
Paris Sud, Faculté de Pharmacie, 5 rue Jean Baptiste
Clément, F92296 Chatenay Malabry Cedex, France, the
h Institut de Recherches Servier, 11 rue des Moulineaux 92150, Suresnes, France, and the i Deutsches Institut für
Ernaehrungsforschung Potsdam (DIfE), German Institute of Human
Nutrition, Arthur Scheunert Allee 114-116,
D-14558 Bergholz-Rehbrucke, Germany
Received for publication, July 8, 2002, and in revised form, September 4, 2002
 |
ABSTRACT |
The mitochondrial uncoupling protein
of brown adipose tissue (UCP1) was expressed in skeletal muscle and
heart of transgenic mice at levels comparable with the amount found in
brown adipose tissue mitochondria. These transgenic mice have a lower
body weight, and when related to body weight, food intake and energy
expenditure are increased. A specific reduction of muscle mass was
observed but varied according to the contractile activity of muscles.
Heart and soleus muscle are unaffected, indicating that muscles
undergoing regular contractions, and therefore with a continuous
mitochondrial ATP production, are protected. In contrast, the
gastrocnemius and plantaris muscles showed a severely reduced mass and
a fast to slow shift in fiber types promoting mainly IIa and IIx fibers at the expense of fastest and glycolytic type IIb fibers. These observations are interpreted as a consequence of the strong potential dependence of the UCP1 protonophoric activity, which ensures a negligible proton leak at the membrane potential observed when mitochondrial ATP production is intense. Therefore UCP1 is not deleterious for an intense mitochondrial ATP production and this explains the tolerance of the heart to a high expression level of UCP1.
In muscles at rest, where ATP production is low, the rise in membrane
potential enhances UCP1 activity. The proton return through UCP1 mimics
the effect of a sustained ATP production, permanently lowering
mitochondrial membrane potential. This very likely constitutes the
origin of the signal leading to the transition in fiber types at rest.
 |
INTRODUCTION |
Uncoupling protein 1 (UCP1)1 is expressed
exclusively in brown adipose tissue (reviewed in Refs. 1 and 2). Its
presence in brown fat mitochondria is responsible for heat production
by the mitochondria in brown adipocytes. UCP1 allows return of protons into the matrix without ATP synthesis, and therefore dissipates the
proton electrochemical gradient built up after proton pumping by the
respiratory complexes. When this gradient reaches high values this
makes proton pumping and thus substrate oxidation less easy and
therefore slows down respiration. Activity of UCP1 prevents this rise
of the proton gradient and therefore allows respiration to occur at a
high rate, without phosphorylation of ADP into ATP, and therefore
energy is instantaneously released as heat. The essential role of the
UCP1 in thermogenesis is illustrated by the cold intolerance of mice
whose ucp1 gene has been disrupted (3). Recently, two genes
coding for proteins highly homologous to UCP1 have been described
(reviewed in Refs. 4-6). Although there are experimental evidence
supporting the hypothesis of an uncoupling activity of these proteins
(7, 8), their physiological relevance is still incompletely resolved
(9-11). We intended to obtain transgenic mice overexpressing the UCP1
in skeletal muscles, with the aim of examining the effects of the
presence of this uncoupling protein on the pattern of myosin expression
and metabolic characteristics of locomotor muscles. Two other reports
published describe transgenic mice either overexpressing UCP3 (12) or expressing relatively modest amounts of UCP1 in muscle (13). In both
cases increased energy expenditure resulted in a lower body weight. Few
or no functional data about the activity of the uncoupling protein
in vivo or in vitro have been produced. In our
model of transgenic mice we have obtained a high expression level of
UCP1 in skeletal muscles and heart. We produce data concerning the
activity of the UCP1 in isolated mitochondria and in vivo using NMR of phosphorylated intermediates. UCP1 expression in skeletal
muscle induced many alterations in muscle mass, myosin composition, and
metabolic characteristics, which were related to the function and
contractile activity of muscles. We examined how these alterations
could be explained by the functional characteristics of UCP1.
 |
EXPERIMENTAL PROCEDURES |
Generation of Transgenic Mice--
By the use of
classical molecular biology techniques, the cDNA coding for the rat
UCP1 associated with the SV40 polyadenylation sequence was ligated at
the BstEII site of the mouse muscle creatine kinase (MCK)
promoter from the
3300MCKCAT construct, kindly provided by Dr. S. Levak Franck and Dr. S. D. Hauschka (14). This
BstEII site is located seven bases downstream of the
transcription start site. Therefore, the MCK promoter drives the
transcription of the rat UCP1 mRNA. A PstI site was
added after the SV40 polyadenylation sequence by site-directed
mutagenesis. This plasmid, called pMCK-UCP1, was used to prepare the
DNA injected into mouse eggs. The integrity of the UCP1 cDNA
sequence was checked by DNA sequencing.
Digestion with PstI released the transgene (MCK promoter,
UCP1 cDNA, SV40 polyadenylation site) free of vector sequences. This fragment called MCK-UCP1 was isolated from an agarose gel by
electroelution. The DNA was microinjected into pronuclei of single cell
embryos obtained from B6D2F1 parents (Iffa-Credo l'Arbresle, France)
and the injected embryos were transplanted into the oviduct of
pseudopregnant foster mothers. After preparation of DNA from tail,
transgenic offspring were identified by PCR amplification of the rat
UCP1 cDNA. Positives thus identified were checked for the integrity
of the transgene by performing Southern blot analysis. Our attempts to
establish stable homozygous lines of both lines have hitherto failed.
Although mating of homozygotes could yield progeny, subsequent mating
failed. Consequently, the animals used were the offspring of matings of
hemizygotes, and control animals were littermates of the transgenics,
which provide the best control available with these progeny of hybrid mice.
Phenotypical Characterization of Mice--
The body weights of
the mice were determined weekly. As controls we used offspring of the
same strain (B6D2F1) that were not transgenic for the MCK-UCP1 gene
including brothers and sisters of the MCK-UCP1-positive mice. The body
weight controls did not differ from the reference value for the B6D2F1
strain determined by the supplier (Iffa Credo, l'Arbresles, France).
Mice (10-46 weeks of age) were sacrificed and dissected to measure the
fresh weight of different organs.
Dual energy x-ray absorptiometry allows the determination of fat
mass (15). The measurements were performed with a PIXImus mouse
densitometer (Lunar France, Lambesc, France). The mice were anesthetized with an intraperitoneal injection of pentobarbital (0.6 mg/kg) (Sanofi, Libourne, France) before scanning and placed with their
stomach down in the PIXImus. The fat percent calculated by the software
was used.
Food intake was determined by estimating the amount of food (chow diet
M25 Pietremont, Provins, France, energy content: 346 kilocalories/100
g) consumed by the mice. Mice (10-30 weeks of age) were housed
individually, and their body weight and food intake was measured at
intervals varying from 1 to 7 days. Cages were inspected for food
spillage but none was noticed. The food intake per day was calculated
for each mouse by dividing the cumulated food intake over the entire
period of the experiment by the total number of days of the experiment.
Energy expenditure of individual mice was measured over 2 days using
indirect calorimetry as described in Ref. 16. In short, oxygen
consumption and CO2 production were determined every 6 min
in an open respirometric system and energy expenditure was calculated
according to Ref. 17. Total energy expenditure was calculated as a 24-h mean.
Isolation and Study of Isolated Mitochondria--
Mice were
killed by cervical dislocation. Muscles from the legs or heart were
collected from 3 to 5 mice. Tissues were chopped with scissors and
homogenized in a Potter homogenizer with a Teflon pestle in the
presence of nargase (Sigma number P4789) at 6-9 mg/ml at 0 °C. A
first centrifugation step at 10,000 × g was used to
eliminate the nargase with the supernatant. The pellet was gently
resuspended in homogenization medium and this suspension was used to
isolate mitochondria by differential centrifugation. Mitochondrial
respiration was monitored with a Clark oxygen electrode (Hansatech,
Norfolk, England), and membrane potential was measured with a home-made
TPP+ electrode following published procedures (18). For
flow cytometry, mitochondria were diluted to a concentration of 2 µg/ml in the respiration medium containing 100 nM
rhodamine 123 (Molecular Probes). Staining in the presence of substrate
was allowed to proceed for approximately 3 min (separate experiments
confirmed that a stable value of fluorescence is reached after 150 s and is maintained up to 5 min). Analysis was done with an EPICS
Coulter XL flow cytometer. Particles (mitochondria) were detected by
means of side scatter.
Characterization of Muscular Fiber Types--
Changes in the
expression of MHC isoforms were examined in two fast twitch and one
mixed skeletal muscles (gastrocnemius, plantaris, and soleus muscles,
respectively). Mice were anesthetized with sodium pentobarbital (70 mg/kg body weight) administered intraperitoneally. Gastrocnemius,
plantaris, and soleus muscles were excised, cleaned of adipose and
connective tissue, and wet weighed. Muscles were slightly stretched to
recoil passively to a roughly resting length, mounted in an embedding
medium (TEK O.C.T. compound), and frozen in isopentane cooled to its
freezing point (
160 °C) by liquid nitrogen. Changes in the
relative amounts of MHC isoforms were assessed using
immunohistochemical detection of MHCs within single muscle fibers, and
SDS-PAGE to separate MHC isoforms in whole muscle.
Serial transverse sections (10 µm thick) were cut from the midbelly
portion in a cryostat maintained at
20 °C and were incubated in a
humid chamber in working solutions of mouse monoclonal antibodies that
reacted either with slow type I (number NCL-MHCS, Novocastra, Newcastle
upon Tyne, United Kingdom), or fast type IIa MHC (SC-71), or all adult
fast and developmentally regulated epitopes but not with slow myosin
(MY-32, Sigma). The avidin-biotin immunohistochemical procedure was
used for the localization of antigen-antibody binding (Vector
Laboratories, Burlingame, CA). A sample of ~400 fibers that were free
from artifacts were randomly selected from fields equally distributed
over the biopsy for single fiber MHC composition. Fibers were
classified according to their staining profile as comprising type I,
type IIa or type IIx, and/or type IIb MHC with the aid of a microscope
linked to a computer-based image analysis system (Visiolab 200, Nikon-France). Negative control slides with omission of the primary
antibodies were randomly included in the immunostaining procedures.
Four to five areas were randomly selected on each sample and the mean
fiber cross-sectional area was determined for fibers containing type I,
type IIa, or type IIx, and/or type IIb (type IIb/IIx fibers) MHC isoforms.
SDS-PAGE analyses were performed according to Talmadge and Roy (19).
Myosin was extracted with 3 volumes of 100 mM sodium pyrophosphate, 5 mM EGTA, and 1 mM
dithiothreitol (pH 8.5). The separating gel solution contained 30%
glycerol, 8% acrylamide-bis (50:1), 0.2 M Tris, 0.1 M glycine, and 0.4% SDS. The composition of the stacking
gel was 30% glycerol, 4% acrylamide-bis (50:1), 70 mM
Tris, 4 mM EDTA, and 0.4% SDS. Electrophoresis was
performed using a Mini-Protean II system (Bio-Rad). Gels were run at a
constant voltage (70 V) for ~28 h, and then stained with Coomassie
Blue. The MHC protein isoform bands were scanned and quantified using a
densitometer system equipped with an integrator (GS-700, Bio-Rad).
31P NMR Measurements--
31P NMR of
mouse gastrocnemius was carried out using a Bruker Biospec 47/50
(Bruker Medizintechnik GmbH, Karlsruhe, Germany) equipped with a 50-cm
bore superconducting magnet operating at 4.7 T. For this
purpose, a 1-cm transmit/receive radiofrequency coil tuned at 81 MHz
was designed to ensure correct localization of the NMR signal. Mice
were anesthetized with sodium pentobarbital and positioned prone in the
magnet. The RF coil was placed close to the
gastrocnemius and proton shimming was done to reach a line width at
half-height of typically 50 Hz for the water resonance. Fully relaxed
31P NMR spectra (100-µs RF pulse, 20-s
interpulse delay, 1024 data points, 128 free induction decays, 30 Hz
Lorentzian filter before Fourier transformation) were acquired within
34 min. Spectra were then analyzed (Igor Wavemetrics, Lake Oswego, OR)
as a sum of Lorentzian-Gaussian line shaped resonances to determine the
areas of the nucleoside triphosphate and the phosphocreatine (PCr)
resonances. The PCr/ATP ratio was calculated as the phosphocreatine to
-nucleoside triphosphate resonance area ratio.
 |
RESULTS |
Transgenic Lines Expressing UCP1 in Muscle and Heart--
Two
independent transgenic lines were obtained. Both express UCP1 mRNA
in skeletal muscles and heart (Fig. 1).
No expression of the UCP1 mRNA was found in liver or brain,
indicating that the tissue specificity of the MCK promoter was retained
in these transgenic lines. However, the expression level of the UCP1
mRNA varies from one muscle to another, and these variations were
not consistent in the two transgenic lines: the MCK-UCP1-13 showed highest expression in the heart, and the MCK-UCP1-20 in the
gastrocnemius. The other muscles examined (soleus and plantaris) showed
relatively similar mRNA levels in both transgenic lines. The
expression of the mitochondrial transcription factor 1 (20, 21) was
examined as well as the expression of the MEF2C transcription factor
(22, 23) (Fig. 1). A quantitative analysis showed no consistent
correlation between UCP1 mRNA and mitochondrial transcription
factor 1 mRNA expression levels nor was there a correlation between
UCP1 mRNA and MEF2C mRNA expression (data not shown).

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of the transgene.
Top, 10 µg of total RNA was loaded in each lane. This
blot was prepared with RNA from female mice. The muscles from 6 hemizygote animals were pooled for mRNA preparation. The blot was
probed with a cDNA containing the entire coding sequence for rat
UCP1 produced by PCR, and labeled with 32P by random
priming. Mitochondrial transcription factor 1 (Tfam) probe
was prepared from the plasmid pDG5 (20), containing the mouse
mitochondrial transcription factor A gene (GenBankTM
accession number U57939). The MEF2C probe (GenBankTM
accession number U30823) was obtained from Dr. M. Buckingham, Institut
Pasteur (Paris). The 18 S rRNA probe was a gift from David Tuil,
Institut Cochin (Paris). The rat cyclophilin probe
(GenBankTM accession number M19533) was prepared from the
p1B15 plasmid (34). These two latter probes were used to assess the
actual quantity of RNA transferred in each lane. Bottom,
Western blot of mitochondrial preparations. 2 µg of protein in each
lane. L, liver; H, heart;
M, skeletal muscle (leg and upper leg);
B, brown adipose tissue. The transgenic line is
indicated (MCK-UCP1-13 or MCK-UCP1-20).
Control, non-transgenic mice.
|
|
The amount of UCP1 in the mitochondria isolated from leg muscles or
heart was estimated by Western blotting (Fig. 1). A similar amount of
UCP1 was found in the skeletal muscle mitochondria of both lines, and
this amount compares well with the level of UCP1 in brown fat
mitochondria. As expected, the two transgenic lines differ with respect
to the amount of UCP1 found in the heart mitochondria with a
significantly higher level found in the MCK-UCP1-13 line.
Phenotypic Alteration of Mice--
The body weight of mice was
measured (see Fig. 2). After 5 weeks
transgenic mice showed an almost stable deficit in body weight of 30%.
Animals were dissected and the weight of different organs was measured.
For most organs (Table I) the relative
weight was unchanged. Brain and liver conserved their absolute weight
and consequently showed a higher relative weight in transgenics (data not shown). The comparison of the lean and fat mass measured by x-ray
tomography (Fig. 2, bottom) indicated that transgenic mice and 64% (7) of their controls shared an identical percentage of body
fat of about 15%. On the other hand, in this experiment 36% (4) of
the control animals had a significantly higher percentage of body fat.
Therefore two types of animals were found in control mice, and the
trend toward a lower percentage of body fat in transgenics is explained
by this heterogeneity of controls. Whatever the cause of this
distribution of body fat percentage in controls, it seems likely that
the presence of UCP1 prevents the occurrence of a higher percentage of
body fat, but does not reduce it to below the 15% found in the
majority of controls. Blood glucose levels in milligrams/dl measured in
the fasted state were 72 ± 7 for males (n = 11)
and 61 ± 3 for females (n = 10) in the control mice. In the transgenic mice the values were 70 ± 7 (n = 10) for males (p = 0.78 with
control) and 51 ± 3 (n = 10) for females (p = 0.057 with control). In the fed state these mice
showed values between 115 and 120 mg/dl with no significant
differences between control and transgenic mice. No differences between
transgenic mice and their controls were found for plasma triglycerides
or cholesterol. However, transgenic mice showed a statistically
significant reduction in plasma creatinine concentration (both males
and females) and in urea (males only), changes that are consistent with
their reduced muscle mass.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
Body weight and percent of fat.
Top, the relative body weight values for females are
indicated for even weeks, whereas the values for males are indicated
for odd weeks. , control mice; females: 3 < n < 26 mean = 11; males: 7 < n < 19 mean = 12. The 100% value is the body weight of control mice at
10 weeks of age (22.4 g ± 0.24, n = 26 for
females; 27.9 ± 0.34, n = 27 for males). These
control mice are brothers and sisters of transgenic mice. refers to
the values determined for the B6D2F1 genotype by the supplier of these
hybrid mice (Iffa Credo), n = 10; , MCK-UCP1-20,
females, 10 < n < 28, mean = 13; males,
6 < n < 22, mean = 13; , MCK-UCP1-13,
females, 3 < n < 12, mean = 8; males,
3 < n < 10, mean = 7. Only three values of
the S.E. are above 5%, therefore error bars are omitted for clarity.
Gray diamonds represent the relative body weight (mean
value, 4 < n < 15) of animals bearing four
insertion sites of the transgene. These mice were obtained by mating
homozygotes of the two transgenic lines. Bottom,
individual values of body weight and percent fat mass determined by
x-ray tomography. Females are symbolized by circles and
males by squares, transgenics (hemizygotes and homozygotes)
are indicated by black symbols, and controls by white
symbols.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Relative organ weight
Organ weight is given in relative values: milligrams of organ per g of
body weight (mean ± S.E.). The number of determinations for each
organ is indicated in parentheses. Since they are very similar, the
values for both transgenic strains (MCK-UCP1-13 and MCK-UCP1-20) were
pooled. Statistical analysis of significance was done with a
t test. The increase in relative weight of brain and liver
results from the fact that the actual weight of these organs was
unchanged between transgenic versus control: brain:
0.43 g ± 0.03 versus 0.43 g ± 0.02, liver:
1.27 g ± 0.20 versus 1.41 g ± 0.27.
|
|
The food intake of transgenic mice was the same as that of the controls
(Table II). Consequently when this food
intake was corrected for body weight, this made the transgenic mice
hyperphagic. Hypermetabolism must compensate for this increased food
intake. Accordingly, the relation between total energy expenditure and body weight was found to be altered in transgenics when compared with
controls (Fig. 3).
View this table:
[in this window]
[in a new window]
|
Table II
Food intake
Four independent experiments were performed over 23, 4, 29, and 28 days. Each experiment involved mice of matched ages. The very similar
values for the MCK-UCP1-13 and MCK-UCP1-20 were pooled. Values for
hemizygote mice and homozygote mice are shown separately to reveal any
gene dosage effect. This remark applies also to Tables III and IV. The
values are mean ± S.E. Statistical significance was determined by
means of Student's t test.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Energy expenditure. Total energy
expenditure was measured over a 24-h period. , control mice; ,
transgenic mice (hemizygotes and homozygotes).
|
|
Alterations in Fiber Type and Myosin Composition--
Skeletal
muscles of transgenic mice showed a reduced weight, which is
illustrated by the significant decrease in the relative mass of the
total leg (Table I). The normalized weights of the plantaris and
gastrocnemius, two fast twitch skeletal muscles, from both MCK-UCP1
lines were markedly lower than those from control mice, whereas the
relative mass of the soleus, a slow twitch skeletal muscle, and heart
remained unchanged (Table III). The
changes in myofiber size were examined in skeletal muscle. No
significant alteration in the mean fiber cross-sectional area of fiber
types I, IIa, or IIx/IIb was shown in soleus muscle as a result of
transgenesis. In contrast, the decrease in absolute and relative
weights of fast twitch muscles resulted mainly from a marked decrease
in the fiber cross-sectional area of fiber types IIa and IIx/IIb:
27%, p < 0.05 and
41%, p < 0.01, respectively, in plantaris muscle;
40 and
42%,
p < 0.01, respectively, in gastrocnemius muscle of
homozygotes. In hemizygote mice, the values were very close:
22%,
p < 0.05, and
35%, p < 0.01, respectively, in plantaris muscle;
36 and
38%, p < 0.01, respectively, in gastrocnemius muscle. In this experiment and
in another independent histological study of muscles, there was no
evidence of increased myofiber necrosis and regeneration in transgenic
mice (data not shown).
View this table:
[in this window]
[in a new window]
|
Table III
Muscle relative weight
Mean ± S.E. of the relative weight (mg/g) of several muscles.
Mice from both strains (MCK-UCP1-13 and MCK-UCP1-20) were included in
these analyses and the results were pooled since no difference was
noted between the two transgenic lines. The statistical significance
was estimated by means of analysis of variance.
|
|
The relative content of MHC isoforms, as estimated by SDS-PAGE
analysis, was affected both in plantaris and gastrocnemius muscles of
MCK-UCP1 mice (Table IV). A fast to slow
shift in myosin isoforms was observed in plantaris muscle from
transgenic mice, with a slight increase in type I MHC
(p < 0.05), a marked increase in type IIa MHC, type
IIx MHC, and a concomitant decrease in the percentage of type IIb MHC
(p < 0.001). Similar results were noted in
gastrocnemius, whereas the MHC composition of the soleus muscle was
unaffected in transgenic mice.
View this table:
[in this window]
[in a new window]
|
Table IV
Myosin isoforms
The mean ± S.E. of the percentage of the different isoforms of
myosin heavy chain. The statistical significance was evaluated by means
of analysis of variance.
|
|
Changes in the fiber type distribution were consistent with alterations
in the relative content of MHC isoforms. A significant increase in the
percentage of fibers containing type I or type IIa MHC was observed in
fast twitch muscles of transgenic mice, in comparison with control
mice, whereas the percentage of type IIx/IIb fibers was decreased. No
modification in fiber type distribution was observed in soleus muscles.
Fig. 4 compares several
enzymatic activities in muscles. Citrate synthase activity and
cytochrome oxidase (data not shown) were used as an index of
mitochondrial abundance. With the notable exception of gastrocnemius,
there was a tendency toward a slightly lower activity of these enzymes
in skeletal muscles and heart of transgenics. On the other hand,
creatine kinase, adenylate kinase (data not shown), and lactate
dehydrogenase, considered as markers of the fast glycolytic fibers,
were significantly decreased in plantaris and gastrocnemius muscle of
transgenics.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Enzyme activities in muscle. Enzymatic
activities are expressed in international units. Values are given as
mean ± S.E. Control, n = 4; transgenics
(hemizygotes), n = 6, three MCK-UCP1-13 and three
MCK-UCP1-20.
|
|
In Vivo 31P NMR--
Typical 31P NMR
spectra of wild-type and MCK-UCP1-13 mouse gastrocnemius at rest are
presented in Fig. 5. The PCr and
nucleoside triphosphate resonances were clearly visible in every
recorded spectrum. Occasionally, an additional resonance at 2.5 ppm
attributable to inorganic phosphate could be detected in transgenic
mice but could never be quantified. All spectra within a group (control or transgenics) were similar, and the spectra presented in Fig. 5 are
representative of all experiments. Muscles from mice expressing the
uncoupling protein always presented a marked decrease in PCr content
relative to ATP. Quantitative data are presented in Table V. The creatine content of muscles was
also measured, in fact we found slightly higher creatine concentrations
in transgenics. These results, clearly indicate that the difference in
the PCr/ATP ratio cannot be explained by a decrease in the creatine
level. Nor is it explained by different maximal enzymatic activities because NMR experiments were done at rest when a steady state was
reached, and when hydrolysis of ATP in muscle was minimal.
View this table:
[in this window]
[in a new window]
|
Table V
PCr to ATP ratio in muscle
PCr to ATP ratio (mean ± S.D.) determined by means of in
vivo NMR. Creatine concentration (mean ± S.E.) in leg
muscles is expressed in nanomole of creatine/mg of muscle protein.
Statistical significance was estimated by means of analysis of
variance.
|
|
Activity of the UCP1 in Muscle or Heart Mitochondria--
Fig.
6 shows the influence of
known activators/inhibitors of UCP1 uncoupling activity on muscle
mitochondria of control mice and transgenics. After inhibition of the
ADP/ATP translocase by carboxyatractylate, addition of palmitic acid
had no effect on the membrane potential or on the respiratory rate of
muscle mitochondria from control mice. Unlike with mitochondria from
transgenics, addition of the same amount of palmitic acid produced a
marked decrease in membrane potential accompanied by an increase in
respiratory rate, both effects being completely reversed after addition
of GDP (Fig. 6A). These antagonistic effects of fatty acid
and GDP revealed the presence of a fully active UCP1 in the
mitochondrial inner membrane (18). Similar results were obtained with
heart mitochondria of MCK-UCP1-13 mice. In Fig. 6B, the
response of muscle mitochondria to ADP is shown before or after GDP
addition. GDP addition had no effect on control muscle mitochondria,
because the two "ADP cycles" occurred identically. In contrast,
before GDP addition transgenic muscle mitochondria showed a
deteriorated ADP response with respect to controls: the respiratory
control was much lower and more time was needed to phosphorylate the
same amount of ADP into ATP. After inhibition of UCP1 by GDP, the ADP cycle occurred as with the control mitochondria.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Respiratory activity. Respiratory
activity and membrane potential of muscle mitochondria in the presence
of 0.04% fatty acid-free bovine serum albumin. Not shown is a first
addition of 75 nmol of ADP for respiratory chain activation and
nucleotide equilibration, and the addition of 67 µM final Ap5A to
inhibit contaminating kinases. The experiments shown were done with
mitochondria from MCK-UCP1-13 males (hemizygotes) and their littermate
controls. Similar results were obtained with mitochondria from the
MCK-UCP1-20 transgenic line. A, effect of palmitic
acid and GDP under state 4 conditions; top, control
mitochondria; bottom, mitochondria from MCK-UCP1 mice. The
values of the respiratory rate in nanomole of O2/min/mg of
protein are indicated below the oxygen electrode trace
(Ox). Membrane potential values in millivolts are indicated
in italics above the TPP+ electrode trace (mV).
Additions: CAT, carboxyatractylate, 1 µM
final; Palm., palmitic acid + 5 µM (increase
of 1 unit in the ratio palmitic acid to albumin); GDP, GDP + 0.5 mM; CCCP, CCCP + 150 nM.
B, response to ADP of muscle mitochondria.
ADP, +150 nmol of ADP. The values of respiratory control
ratios are indicated. The rest of the legend is as above.
|
|
In the stationary state, the backflow of protons across the inner
membrane compensates for the proton pumping by the respiratory chain.
If we assume a constant stoichiometry between proton pumping by the
respiratory chain and oxygen consumption, then the backflow of protons
across the inner membrane is linearly related to the respiratory rate.
According to Ohm's law the proton flux is determined by both the
membrane potential and membrane conductance. The curves showing the
resulting membrane potentials for the decreasing state 4 respiratory
rates generated after gradual inhibition of succinate dehydrogenase by
malonic acid could be used to calculate the conductance of the inner
membrane to protons at variable membrane potentials. This curve is
modified in mitochondria from transgenics (Fig. 7). Addition of albumin (fatty acid
chelator) diminishes the conductance, as does GDP. Finally, in the
presence of both inhibitors (GDP + albumin) the conductance of the
mitochondrial inner membrane of transgenics is unchanged in comparison
to control. Therefore the protonophoric activity of the UCP1 can be
fully inhibited whatever the value of the membrane potential. Neither
GDP nor albumin alone could lead to full inhibition of UCP1 in
mitochondria, both are requested. This calls to mind the observation
made a long time ago with brown adipose tissue mitochondria where UCP1 is naturally present (24). If the conductance of the membrane were
constant for all potential values, the curves would be straight lines.
This is not the case, at low membrane potential values the conductance
remains relatively low, whereas at higher potentials the conductance
increases abruptly. When UCP1 is absent or inactive, the respiratory
rate (conductance) increases 6-10-fold between 130 mV, the value of
potential in state 3 (Fig. 6B), and the maximal value
attained in state 4 (>170 mV). Although less marked, this "non-ohmicity" of the curves is still apparent in the presence of
UCP1, and the difference in proton leakage at the potential observed in
state 3 (130 mV) and the maximal value in state 4 remains considerable
as soon as UCP1 is partially inhibited.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Force-flux relationships. Force-flux
relationships of mitochondria in state 4. All experiments were
performed in the presence of oligomycin 0.1 µg/ml final,
Ap5A, and carboxyatractylate. Top, muscle
mitochondria: , MCK-UCP13 in the absence of bovine serum albumin;
, MCK-UCP13 in the presence of 0.2% bovine serum albumin; ,
MCK-UCP1-13 in the presence of 2% bovine serum albumin and 3 mM GDP; , control in the presence of bovine serum
albumin. Bottom, heart mitochondria: , MCK-UCP13 in the
absence of bovine serum albumin; , MCK-UCP13 in the presence of 3 mM GDP; , MCK-UCP13 in the presence of 0.2% bovine
serum albumin; , MCK-UCP1-13 in the presence of 0.2% bovine serum
albumin and 3 mM GDP.
|
|
Mitochondrial Oxidation of
L-
-Glycerophosphate--
The comparison of mitochondria
from type IIb and type I fibers (25) showed that the glycerophosphate
dehydrogenase is present at a 10 times higher level in mitochondria
from type IIb fibers. The relative oxidation of succinate and of
L-
-glycerophosphate by muscle mitochondria from
wild-type and transgenic mice is shown in Fig.
8, ADP and the uncoupler CCCP were added
to increase the respiratory rate and thus to evidence the respiratory
control. The conditions used led to complete inhibition of the UCP1 and no difference was found in the presence of succinate. At the opposite, in the presence of L-
-glycerophosphate mitochondria from
transgenics failed to show an increase in respiratory rate after
addition of ADP or CCCP indicating a poor capacity of these
mitochondria to use L-
-glycerophosphate as a substrate.
Under the same conditions, the membrane potential of individual
mitochondria was evaluated by rhodamine 123 staining and flow cytometry
(Fig. 9). A large majority of the
particles showed energization upon addition of substrate (true
mitochondria), but a minority remained at the fluorescence values
observed in the absence of membrane potential (non-mitochondrial
particles or damaged mitochondria). In the presence of succinate,
energizing particles (mitochondria) from transgenic muscles reached the
same value of membrane potential as the controls. With
L-
-glycerophosphate the fluorescence of the whole
population was lower than with succinate. Moreover, no mitochondria
were able to reach the high potential values attained in the presence
of succinate. L-
-Glycerophosphate led to an almost identical energization of mitochondria from transgenic mice, which is
not contradictory to the experiment shown in Fig. 8, because a very
modest respiratory rate is able to support energization of
mitochondria, whereas response to ADP and uncoupler required a
significant increase in the respiratory rate. In fact the distribution obtained with mitochondria from transgenic mice showed a slightly higher frequency in the lower fluorescence values, which reflects the
reduced ability of these mitochondria to utilize
L-
-glycerophosphate.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 8.
Oxidation of
L- -glycerophosphate. Comparison of the oxidation of
L- -glycerophosphate and succinate in the presence of 1 mM GDP by mitochondria from control (gray trace)
or from transgenic (black trace) mice. Additions are
indicated: aGP, L- -glycerophosphate, 5 mM
final; succinate, 5 mM final; ADP, 10 0 µM
final; oligomycin, +0.5 µg/ml oligomycin; black
arrows, +0.5 µM CCCP.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 9.
Flow cytometry of mitochondria.
Histogram of rhodamine 123 fluorescence of muscle mitochondria. 10,000 objects (mitochondria) were used to draw histograms. Mitochondria were
incubated in the presence of 1 mM GDP and 5 mM
L- -glycerophosphate (solid line), or in the
presence of 1 mM GDP and 5 mM succinate
(dotted lines). Black, mitochondria from control
mice. Red, mitochondria from MCK-UCP1-13 mice.
Blue, mitochondria from MCK-UCP1-20 mice. Green
histogram, mitochondria (control mice) poisoned with 1 mM cyanide and 1 µM CCCP (membrane potential
down to zero). Poisoned mitochondria from transgenic mice displayed the
same histogram.
|
|
 |
DISCUSSION |
Two recently published reports have described how a moderate
expression of UCP1 (13) or an enhancement of the expression of UCP3
(12) in the muscle of transgenic mice results in a resistance to
diabetes and obesity. This is well in line with the idea that expression of a bona fide uncoupling protein such as UCP1 or
overexpression of its close homologue (UCP3) found in muscle is able to
increase energy expenditure by mitochondrial uncoupling. Therefore
these experiments illustrate how the recruitment of uncoupling proteins could help in the treatment of metabolic disorders like overweight and
obesity in man. Our model of transgenic mice produced a slightly different phenotype probably because we obtained higher expression levels of UCP1 in muscle. Actually mice with similar properties have
probably been obtained (13), but little characterization of the effects
of the UCP1 overexpression on muscle contractile and metabolic
phenotypes were provided, nor was the activity of the uncoupling
protein in muscle mitochondria examined.
Our transgenic mice showed a significant reduction in body weight with
a normal chow diet. It seems that we have attained a maximal effect of
the UCP1 because increasing the copy number of the transgene by mating
the two transgenic lines together did not decrease body weight further
(Fig. 2). Moreover, in subsequent experiments no significant difference
was observed when a distinction was made between hemizygote and
homozygote mice for the transgene (Tables II-IV). Similarly, no
difference in the phenotypical alterations provided by the transgene
was found between the two transgenic lines (Fig. 3, Table IV). The food
intake of transgenic mice equaled that of controls but their reduced
body weight made them hyperphagic when the food intake was expressed
relative to body weight (Table I). The relationship between energy
expenditure and body weight is shifted toward hypermetabolism in
transgenic mice (Fig. 3), indicating that UCP1 is likely to be active
as an uncoupler in muscle in vivo. This conclusion is
strengthened by the observation that despite a normal total creatine
content, the ratio between phosphocreatine and ATP at rest is decreased
in transgenics. The relative contribution of muscles to the body weight
is decreased, whereas it is unchanged or even increased for the other
organs studied (Table I). The case of the adipose tissue is of special interest (Fig. 2): whereas no difference was found in the percent body
fat between transgenics and most of the controls, it seems likely that
the presence of UCP1 prevented the rise in body fat percentage observed
in several of the control animals. The reduction in muscle mass was
mainly observed in fast muscles and explained by a decreased fiber
cross-sectional area of fast twitch fibers but likely also by a shift
toward type IIx and IIa fibers, at the expense of type IIb, this latter
type being known as thicker (26). As expected, this fast to slow
transition in fiber type composition was paralleled by concomitant
decreases in the activity of creatine kinase and lactate
dehydrogenase, two mainly glycolytic enzymes (Fig. 4). It was
also seen in isolated mitochondria because muscle mitochondria from
transgenic mice had a reduced ability to oxidize
-glycerophosphate
(Figs. 8 and 9). Finally, our model of transgenesis indicates that a
high amount of functional UCP1 in heart mitochondria seems to have no
influence on the heart under normal conditions. A first explanation
would be that endogenous concentrations of nucleotides keep UCP1
completely inhibited in the heart. A second explanation would be that
regular contraction, hence a high ATP demand, would render UCP1 without
influence on cardiac muscle metabolism, and on differentiation. This
second explanation is consistent with the observations made in skeletal muscles: the soleus, a slow twitch postural muscle, predominantly composed of slow oxidative fibers, recruited during quiet standing and
overground locomotion (27), is protected from the effects of UCP1
expression and maintains its normal fiber composition (Table IV). In
contrast, the plantaris and gastrocnemius showed a significant decrease
in their mass, glycolytic capacity, and type IIb MHC isoform content.
The mechanism by which the presence of UCP1 may have different effects
according to the contractile activity of different muscles could be
easily explained by the dependence of the proton leak through UCP1 on
the membrane potential value (Fig. 7), compared with the values of
membrane potential shown in Fig. 6B: 130 mV when
phosphorylation occurred (state 3), and 170 mV after conversion of all
the ADP into ATP (state 4) when a maximal value of the ATP/ADP ratio
was reached. As we said before, UCP1 is very likely to be active as an
uncoupler in the muscle of transgenic mice. On the other hand it is
very likely that the endogenous concentrations of nucleotides maintain it under partial inhibition. One may therefore conclude that the state
of UCP1 in vivo ranges between the extreme situations of no
inhibition (black circles) and complete inhibition
(black squares), shown in Fig. 7. Accordingly in state 3, with a membrane potential of 130 mV, the fraction of the respiratory
rate diverted from ATP synthesis can be deduced from the
ordinate in Fig. 7. It appears that it is a minor or
negligible fraction in comparison with the value of the respiratory
rate in state 3, which exceeds 100 nmol of O2/min/mg of
protein (Fig. 6B). However, when mitochondria are in state 4 the rise in membrane potential dramatically enhances the influence of
UCP1, for example, in Fig. 7 at 170 mV the proton leak because of the
incompletely inhibited UCP1 (white circles) almost doubled
the respiratory rate in comparison with the situation of complete
inhibition in muscle mitochondria. In heart mitochondria the influence
was even more dramatic because the incompletely inhibited UCP1
prevented the membrane potential reaching the value of 170 mV,
something also observed under the conditions used for the traces shown
in Fig. 6. Therefore in muscles undergoing sustained or repetitive
contractions, where mitochondria operate in state 3, UCP1 would induce
a marginal loss of metabolic energy, whereas in muscles at rest where
mitochondria are expected to operate in a state close to state 4, UCP1
would induce a significant increase in mitochondrial respiration and a
decreased membrane potential. In this respect, "from the point of
view of the mitochondrial respiratory chain," the presence of UCP1
mimics a moderate but continuous ATP production.
The hypothesis that UCP1 has virtually no effect when ATP production is
intense is not in contradiction with the results of the NMR experiment,
because the latter was done at rest. Consequently, muscle mitochondria
are expected to be mainly in state 4, and the UCP1 effect would be the
strongest. The creatine kinase reaction is assumed to be near
equilibrium (28) and the PCr/ATP ratio negatively correlates with
cytosolic free ADP (29). The observed decrease in PCr/ATP ratio thus
indicates an increase in cytosolic ADP in transgenic mice. In terms of
inorganic phosphate, any change would be an increase in transgenic
mice. This increase in ADP therefore reflects a decrease in
phosphorylation potential. According to Mitchell's theory the latter
would be the consequence of an impaired 
H+
across the inner membrane and the decrease in the PCr/ATP ratio is a
direct consequence of the UCP1 protonophoric activity. An alternative
could be that type IIb fibers, which are less abundant in transgenics,
have the highest PCr/ATP ratios, in which case the decrease in the PCr
to ATP ratio would be an indirect consequence of the UCP1 expression.
In type IIb fibers, ATP mainly stems from glycolysis metabolism and
therefore this indicates that glycolysis would allow higher PCr/ATP
ratios to be reached. However, it is still expected that these PCr/ATP
ratios equilibrate with the maximal membrane potential of mitochondria, otherwise ATP would be used by mitochondria. Consequently, this would
predict that control mice possess more mitochondria, thereby sustaining
a higher membrane potential in the presence of substrate. This is
poorly supported by our experimental data with flow cytometry that
allows the detection of subpopulations. First
L-
-glycerophosphate failed to produce in any
mitochondria a polarization as high as succinate, and second the upper
limits of membrane potential (fluorescence) seemed almost identical in
controls and transgenics (Fig. 7). This therefore suggests that the
decreased PCr/ATP ratio directly reflects UCP1 uncoupling activity
rather than its indirect consequences on muscular differentiation.
One of the interesting findings of this study was the fast to slow
change in MHC composition observed in fast muscles of transgenic mice.
Fast twitch muscles commonly have a low contractile activity, a
condition where UCP1 is expected to have the strongest influence on
mitochondrial metabolism. Therefore, the present results suggests that
a signaling pathway must originate from mitochondria, which ultimately
drives toward differentiation of myofibers associated with a more
oxidative metabolism. This signaling pathway is independent of ATP
turnover, mechanical factors, and neuronal drive. The slightly increased substrate oxidation at rest remains a candidate as well as a
variable influenced by mitochondrial 
H+ or
cytosolic
GP. The exact mechanisms underlying fiber-type transitions
remain to be elucidated and the control of the expression of genes
encoding contractile and metabolic proteins has not been clearly
identified to date. Previous studies showed that chronic administration
of
-guanidinopropionic acid, a chemical that decreases the PCr/ATP ratio in muscle, induced a switch from fast to slow myosin isoforms (30). The results of the present study are in accordance with these
findings and suggest that the energy potential of muscle fibers could
play a regulatory role in determining the muscle phenotype (31).
However, no direct molecular link between the PCr/ATP ratio and the
control of gene transcription has been clearly identified to date.
Present knowledge of the molecular mechanisms of myosin and enzymatic
protein expression suggests that a prolonged increase in cytosolic
calcium concentration explains the preferential transcription of genes
associated with the slow oxidative muscle phenotype (32, 33). In
resting muscles, UCP1 activity results in a decrease in the
mitochondrial 
H+ and cytosolic phosphorylation potentials. Both would lead to a decrease in the gradient of calcium between sequestration spaces (sarcoplasmic reticulum and/or
mitochondria) leading to an increase in cytosolic calcium
concentration. This would explain, at least partly, the observed shift
toward a less fast muscular phenotype. However, no significant change
in the activity of citrate synthase, a mitochondrial enzyme, was
associated with the decreased expression of the fastest myosin isoform
in fast muscles. It has been hypothesized that the imbalance between energy requirement and energy supply may explain the responses of
muscle to endurance training. However, the fast to slow conversion observed in transgenic mice differs from that in skeletal muscle after
endurance training, which is mainly characterized by an increase in
oxidative capacity. This suggests either that distinctive pathways
control the expression of genes of the oxidative metabolism, or that
there is a gradation of the effects according to the extent of
mitochondrial recruitment. This latter hypothesis may be explained because in these transgenic mice the increase in mitochondrial respiratory activity because of UCP1 in state 4 is expected to be
marginal in comparison with the full respiratory capacity of mitochondria, and the decrease in membrane potential modest with regard
to the decrease induced by oxidative phosphorylation in state 3. This
study gives an example where modifications of mitochondrial characteristics, regardless of the ATP production rate, influence gene expression.
 |
ACKNOWLEDGEMENTS |
We thank Marie France Chapey for technical
assistance, and Laurence Bernard, Danielle Chamereau, and Edwige
Declercq for dedicated care to animals.
 |
FOOTNOTES |
*
This work was supported by the Centre National de la
Recherche Scientifique, Institut National de la Santé et de la
Recherche Médicale, and grants from the Association pour la
Recherche sur le Cancer (to F. B.), the Human Frontier Science
Program, and the Institut de Recherches Servier (to D. R.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b
Supported by a grant from the Institut de Recherches Servier.
d
Established investigator of the Ecole Pratique des Hautes Etudes.
j
To whom correspondence should be addressed: CNRS-UPR 9078, Institut de Recherches Necker Enfants Malades, 156 rue de Vaugirard, 75730 Paris Cedex 15, France. E-mail: bouillau@infobiogen.fr.
Published, JBC Papers in Press, September 6, 2002, DOI 10.1074/jbc.M206726200
 |
ABBREVIATIONS |
The abbreviations used are:
UCP1, uncoupling protein 1;
MCK, muscle creatine kinase;
MHC, myosin heavy
chain;
PCr, phosphocreatine;
CCCP, carbonyl cyanide
p-chlorophenylhydrazone;
Ap5A, P1,P5-di(adenosine
5')-pentaphosphate.
 |
REFERENCES |
| 1.
|
Nicholls, D. G.,
and Locke, R. M.
(1984)
Physiol. Rev.
64,
1-64[Free Full Text]
|
| 2.
|
Klingenberg, M.,
Echtay, K. S.,
Bienengraeber, M.,
Winkler, E.,
and Huang, S. G.
(1999)
Int. J. Obes. Relat. Metab. Disord.
23 Suppl. 6,
S24-S29
|
| 3.
|
Enerback, S.,
Jacobsson, A.,
Simpson, E. M.,
Guerra, C.,
Yamashita, H.,
Harper, M. E.,
and Kozak, L. P.
(1997)
Nature
387,
90-94[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Boss, O.,
Hagen, T.,
and Lowell, B. B.
(2000)
Diabetes
49,
143-156[Abstract]
|
| 5.
|
Bouillaud, F.,
Couplan, E.,
Pecqueur, C.,
and Ricquier, D.
(2001)
Biochim. Biophys. Acta
1504,
107-119[Medline]
[Order article via Infotrieve]
|
| 6.
|
Ricquier, D.,
and Bouillaud, F.
(2000)
Biochem. J.
345,
161-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Rial, E.,
Gonzalez-Barroso, M.,
Fleury, C.,
Iturrizaga, S.,
Sanchis, D.,
Jimenez-Jimenez, J.,
Ricquier, D.,
Goubern, M.,
and Bouillaud, F.
(1999)
EMBO J.
18,
5827-5833[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Echtay, K. S.,
Winkler, E.,
Frischmuth, K.,
and Klingenberg, M.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1416-1421[Abstract/Free Full Text]
|
| 9.
|
Vidal-Puig, A. J.,
Grujic, D.,
Zhang, C. Y.,
Hagen, T.,
Boss, O.,
Ido, Y.,
Szczepanik, A.,
Wade, J.,
Mootha, V.,
Cortright, R.,
Muoio, D. M.,
and Lowell, B. B.
(2000)
J. Biol. Chem.
275,
16258-16266[Abstract/Free Full Text]
|
| 10.
|
Gong, D. W.,
Monemdjou, S.,
Gavrilova, O.,
Leon, L. R.,
Marcus-Samuels, B.,
Chou, C. J.,
Everett, C.,
Kozak, L. P., Li, C.,
Deng, C.,
Harper, M. E.,
and Reitman, M. L.
(2000)
J. Biol. Chem.
275,
16251-16257[Abstract/Free Full Text]
|
| 11.
|
Arsenijevic, D.,
Onuma, H.,
Pecqueur, C.,
Raimbault, S.,
Manning, B. S.,
Miroux, B.,
Couplan, E.,
Alves-Guerra, M. C.,
Goubern, M.,
Surwit, R.,
Bouillaud, F.,
Richard, D.,
Collins, S.,
and Ricquier, D.
(2000)
Nat. Genet.
26,
435-439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Clapham, J. C.,
Arch, J. R.,
Chapman, H.,
Haynes, A.,
Lister, C.,
Moore, G. B.,
Piercy, V.,
Carter, S. A.,
Lehner, I.,
Smith, S. A.,
Beeley, L. J.,
Godden, R. J.,
Herrity, N.,
Skehel, M.,
Changani, K. K.,
Hockings, P. D.,
Reid, D. G.,
Squires, S. M.,
Hatcher, J.,
Trail, B.,
Latcham, J.,
Rastan, S.,
Harper, A. J.,
Cadenas, S.,
Buckingham, J. A.,
Brand, M. D.,
and Abuin, A.
(2000)
Nature
406,
415-418[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Li, B.,
Nolte, L. A., Ju, J. S.,
Han, D. H.,
Coleman, T.,
Holloszy, J. O.,
and Semenkovich, C. F.
(2000)
Nat. Med.
6,
1115-1120[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Jaynes, J. B.,
Chamberlain, J. S.,
Buskin, J. N.,
Johnson, J. E.,
and Hauschka, S. D.
(1986)
Mol. Cell. Biol.
6,
2855-2864[Abstract/Free Full Text]
|
| 15.
|
Sjogren, K.,
Hellberg, N.,
Bohlooly, Y. M.,
Savendahl, L.,
Johansson, M. S.,
Berglindh, T.,
Bosaeus, I.,
and Ohlsson, C.
(2001)
J. Nutr.
131,
2963-2966[Abstract/Free Full Text]
|
| 16.
|
Klaus, S.,
Munzberg, H.,
Truloff, C.,
and Heldmaier, G.
(1998)
Am. J. Physiol.
274,
R287-R293[Medline]
[Order article via Infotrieve]
|
| 17.
|
Weir, J. B.
(1949)
J. Physiol.
109,
1-9[Free Full Text]
|
| 18.
|
Locke, R. M.,
Rial, E.,
Scott, I. D.,
and Nicholls, D. G.
(1982)
Eur. J. Biochem.
129,
373-380[Medline]
[Order article via Infotrieve]
|
| 19.
|
Talmadge, R. J.,
and Roy, R. R.
(1993)
J. Appl. Physiol.
75,
2337-2340[Abstract/Free Full Text]
|
| 20.
|
Larsson, N. G.,
Garman, J. D.,
Oldfors, A.,
Barsh, G. S.,
and Clayton, D. A.
(1996)
Nat. Genet.
13,
296-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Gordon, J. W.,
Rungi, A. A.,
Inagaki, H.,
and Hood, D. A.
(2001)
J. Appl. Physiol.
90,
389-396[Abstract/Free Full Text]
|
| 22.
|
McDermott, J. C.,
Cardoso, M. C., Yu, Y. T.,
Andres, V.,
Leifer, D.,
Krainc, D.,
Lipton, S. A.,
and Nadal-Ginard, B.
(1993)
Mol. Cell. Biol.
13,
2564-2577[Abstract/Free Full Text]
|
| 23.
|
Leifer, D.,
Krainc, D., Yu, Y. T.,
McDermott, J.,
Breitbart, R. E.,
Heng, J.,
Neve, R. L.,
Kosofsky, B.,
Nadal-Ginard, B.,
and Lipton, S. A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1546-1550[Abstract/Free Full Text]
|
| 24.
|
Nicholls, D. G.,
and Lindberg, O.
(1973)
Eur. J. Biochem.
37,
523-530[Medline]
[Order article via Infotrieve]
|
| 25.
|
Jackman, M. R.,
and Willis, W. T.
(1996)
Am. J. Physiol.
270,
C673-C678[Medline]
[Order article via Infotrieve]
|
| 26.
|
Sieck, G. C.,
Zhan, W. Z.,
Prakash, Y. S.,
Daood, M. J.,
and Watchko, J. F.
(1995)
J. Appl. Physiol.
79,
1629-1639[Abstract/Free Full Text]
|
| 27.
|
Booth, F. W.,
and Thomason, D. B.
(1991)
Physiol. Rev.
71,
541-585[Free Full Text]
|
| 28.
|
Veech, R. L.,
Lawson, J. W.,
Cornell, N. W.,
and Krebs, H. A.
(1979)
J. Biol. Chem.
254,
6538-6547[Abstract/Free Full Text]
|
| 29.
|
Lawson, J. W.,
and Veech, R. L.
(1979)
J. Biol. Chem.
254,
6528-6537[Abstract/Free Full Text]
|
| 30.
|
Ren, J. M.,
Ohira, Y.,
Holloszy, J. O.,
Hamalainen, N.,
Traub, I.,
and Pette, D.
(1995)
Pflugers Arch.
430,
389-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Pette, D.
(1998)
Acta Physiol. Scand.
162,
367-376[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Chin, E. R.,
Olson, E. N.,
Richardson, J. A.,
Yang, Q.,
Humphries, C.,
Shelton, J. M., Wu, H.,
Zhu, W.,
Bassel-Duby, R.,
and Williams, R. S.
(1998)
Genes |